about
Phencyclidine (PCP)-induced disruption in cognitive performance is gender-specific and associated with a reduction in brain-derived neurotrophic factor (BDNF) in specific regions of the female rat brainImpaired limbic cortico-striatal structure and sustained visual attention in a rodent model of schizophrenia.The preclinical profile of asenapine: clinical relevance for the treatment of schizophrenia and bipolar mania.Acute and chronic effects of NMDA receptor antagonists in rodents, relevance to negative symptoms of schizophrenia: a translational link to humans.Assessment of disease-related cognitive impairments using the novel object recognition (NOR) task in rodents.A systematic review and meta-analysis of cognitive remediation in early schizophrenia.A systematic review comparing sex differences in cognitive function in schizophrenia and in rodent models for schizophrenia, implications for improved therapeutic strategies.Lu AE58054, a 5-HT6 antagonist, reverses cognitive impairment induced by subchronic phencyclidine in a novel object recognition test in rats.Effects of asenapine, olanzapine, and risperidone on psychotomimetic-induced reversal-learning deficits in the rat.Attenuation of phencyclidine-induced object recognition deficits by the combination of atypical antipsychotic drugs and pimavanserin (ACP 103), a 5-hydroxytryptamine(2A) receptor inverse agonist.Positive modulation of alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptors reverses sub-chronic PCP-induced deficits in the novel object recognition task in rats.Olanzapine-induced weight gain in the rat: role of 5-HT2C and histamine H1 receptors.Pay attention to impulsivity: modelling low attentive and high impulsive subtypes of adult ADHD in the 5-choice continuous performance task (5C-CPT) in female rats.The atypical antipsychotic ziprasidone, but not haloperidol, improves phencyclidine-induced cognitive deficits in a reversal learning task in the rat.D₁ receptor activation improves vigilance in rats as measured by the 5-choice continuous performance test.H(1)-histamine receptor affinity predicts short-term weight gain for typical and atypical antipsychotic drugs.Correlation of hyperforin content of Hypericum perforatum (St John's Wort) extracts with their effects on alcohol drinking in C57BL/6J mice: a preliminary study.Assessment of cognitive function across pregnancy using CANTAB: a longitudinal study.Effects of the atypical antipsychotic olanzapine on reproductive function and weight gain in female rats.Effects of the classical antipsychotic haloperidol and atypical antipsychotic risperidone on weight gain, the oestrous cycle and uterine weight in female rats.Ziprasidone suppresses olanzapine-induced increases in ingestive behaviour in the rat.Evidence for serotonergic modulation of sucrose sham-feeding in the gastric-fistulated rat.Role of 5-HT receptor mechanisms in sub-chronic PCP-induced reversal learning deficits in the rat.Subchronic effects of phencyclidine on dopamine and serotonin receptors: implications for schizophrenia.D(1)-like receptor activation improves PCP-induced cognitive deficits in animal models: Implications for mechanisms of improved cognitive function in schizophrenia.Effects of subchronic phencyclidine on behaviour of female rats on the elevated plus maze and open field.Investigation into the effects of the novel antipsychotic ziprasidone on weight gain and reproductive function in female rats.Effects of sub-chronic antipsychotic drug treatment on body weight and reproductive function in juvenile female rats.Investigation into the influence of a high fat diet on antipsychotic-induced weight gain in female rats.A preliminary investigation into the effects of antipsychotics on sub-chronic phencyclidine-induced deficits in attentional set-shifting in female rats.Oestradiol attenuates the cognitive deficit induced by acute phencyclidine treatment in mature female hooded-Lister rats.Ziprasidone and aripiprazole attenuate olanzapine-induced hyperphagia in rats.Asenapine improves phencyclidine-induced object recognition deficits in the rat: evidence for engagement of a dopamine D1 receptor mechanism.Efficacy of antipsychotics to reverse phencyclidine-induced social interaction deficits in female rats--a preliminary investigation.The effect of atypical and classical antipsychotics on sub-chronic PCP-induced cognitive deficits in a reversal-learning paradigm.NMDA receptor antagonist rodent models for cognition in schizophrenia and identification of novel drug treatments, an update.Effects of cariprazine, a novel antipsychotic, on cognitive deficit and negative symptoms in a rodent model of schizophrenia symptomatology.The involvement of distraction in memory deficits induced by NMDAR antagonism: relevance to cognitive deficits in schizophrenia.Specific effect of putative 5-HT1A agonists, 8-OH-DPAT and gepirone, to increase hypertonic saline consumption in the rat: evidence against a general hyperdipsic action.Extrasynaptic GABAA receptor activation reverses recognition memory deficits in an animal model of schizophrenia.
P50
Q28584244-6C1C82E6-9FBF-4C1B-8257-23BD1D2E8080Q30403790-390B1040-3EC3-4E36-9FB3-2D21BCA00266Q38057380-BEE8F532-97ED-4E88-BC54-C2F133FFB73BQ38167162-6B860F4B-9BD1-42CC-B2F5-05A7042927F3Q38275147-9A280438-C2D4-4A01-B887-2558610767A8Q38573451-AD576F63-2EA1-47FC-9987-4A75ADFAD6A9Q38876954-9985479E-0C65-4CE3-933A-A6AF14825F70Q43009339-5D64A96D-6E55-421B-89D6-F3D98B54C7FDQ43012518-B8CC0EE5-7B81-4F48-B5BE-9F066E6EA338Q43253183-954C9ACA-266B-42C0-A4B1-9D8171315E5BQ43263162-E3ABD965-D1CA-4923-B538-0BE642A599F5Q43290436-BDC0225C-6584-4414-8D55-928C59B99FBBQ43939860-9EBB3342-508D-49F4-B665-024B794C8CD1Q44393719-E0B1FA9C-7A01-4D61-A92F-96E3A3666917Q44543014-810ADCA9-D457-4AAF-9FC0-B132CBF71B41Q44564341-D2117E17-FBF0-4873-8367-2C3A9C6370EDQ44761168-8E2DF69E-B759-4432-A3DA-46857D7B1D12Q44831263-74A3963D-D030-43B0-853F-A2C88E352958Q44983975-E3F5BBBF-2DA9-4A85-A0E9-F3DBA472831EQ45035640-CC1D4F2E-C896-4799-BADE-53206FFFB1DBQ45157820-6889AA5A-8520-4ACF-83B8-ABF467D14E6EQ45729026-4B1B31F1-9064-4675-8332-34AFB3A86731Q45921170-6539A267-D6E5-4D79-8345-823C138F8FD7Q46004595-2C55B0CA-15CF-40A8-942E-753504AA04BBQ46096827-57665546-1D4D-427D-8452-E5FA5B4F8FECQ46098820-E4FB4D1A-77DF-4D12-82EF-A3639ACEBC27Q46465365-24B9BF35-25A7-40C2-83E5-59306792FC6FQ46703910-6B7249B2-1BF9-447F-8B8E-FE55F02E8F0FQ46726982-AA317C45-160F-42EE-9B87-621C3C798AF0Q46747113-FF4072DE-08EE-421F-80F4-530DA5F26DD6Q46798690-89EFACD5-EED1-4456-BE1A-B6433FD28D5FQ46798743-3E70551A-8D7C-41EC-BD92-1152DA1F35A4Q46859633-DE360197-175F-4B24-9217-0941C4E471F2Q46883271-8D7C3295-77C6-4124-A8CA-D0EFEBA545ADQ46962812-C2F83924-CA70-4597-BF0B-B1C5616CA85AQ47382064-9194ADA1-4562-4317-A4DE-BF66D0D70DDAQ47589373-0E69C9E2-5CEE-4B63-B966-C51255AA2511Q47789463-746FFC2F-CB3C-4FE7-986B-6F4394FAB378Q48158432-7D7C3646-4B24-4EEA-A255-478CB4EA6FF7Q48177435-9A580E2B-B2E7-4B92-B175-D0FBE795D1A7
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Jo C. Neill
@ast
Jo C. Neill
@en
Jo C. Neill
@es
Jo C. Neill
@nl
Jo C. Neill
@sl
type
label
Jo C. Neill
@ast
Jo C. Neill
@en
Jo C. Neill
@es
Jo C. Neill
@nl
Jo C. Neill
@sl
altLabel
Jo Neill
@en
Joanna neill
@en
prefLabel
Jo C. Neill
@ast
Jo C. Neill
@en
Jo C. Neill
@es
Jo C. Neill
@nl
Jo C. Neill
@sl
P1053
L-5155-2016
P106
P1153
56888921100
P31
P3829
P496
0000-0002-2717-9739